Feb 9 (Reuters) - Immunogen Inc:
* IMMUNOGEN REPORTS PIPELINE PROGRESS AND 2017 OPERATING RESULTS
* QTRLY NET LOSS PER COMMON SHARE, BASIC AND DILUTED $0.11
* QTRLY TOTAL REVENUES $39.45 MILLION VERSUS $13.85 MILLION
* IMMUNOGEN - EXPECTS CURRENT CASH COMBINED WITH EXPECTED CASH REVS FROM PARTNERS & COLLABORATORS WILL ENABLE CO TO FUND ITS OPERATIONS INTO Q4 OF 2019
* Q4 EARNINGS PER SHARE VIEW $-0.12, REVENUE VIEW $32.7 MILLION — THOMSON REUTERS I/B/E/S
* SEES CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2018 BETWEEN $115 MILLION AND $120 MILLION
* FY2018 REVENUE VIEW $58.7 MILLION — THOMSON REUTERS I/B/E/S
* IMMUNOGEN SAYS TO MOVE TO OPERATING MODEL THAT WILL RELY ON EXTERNAL MANUFACTURING AND QUALITY TESTING FOR DRUG SUBSTANCE
* IMMUNOGEN - TO MOVE TO OPERATING MODEL THAT WILL ALSO RELY ON EXTERNAL MANUFACTURING AND QUALITY TESTING FOR DRUG PRODUCT FOR DEVELOPMENT PROGRAMS
* DECOMMISSIONING NORWOOD FACILITY WILL RESULT IN ANTICIPATED COST SAVINGS OF OVER $20 MILLION DURING NEXT FIVE YEARS
* IMMUNOGEN -IMPLEMENTING NEW OPERATING MODEL TO LEAD TO RAMP-DOWN OF MANUFACTURING, QUALITY ACTIVITIES AT NORWOOD, MASSACHUSETTS FACILITY BY 2018 END
* IMPLEMENTATION OF NEW OPERATING MODEL WILL LEAD TO FULL EXIT AT NORWOOD, MASSACHUSETTS FACILITY BY EARLY 2019
* Q4 EARNINGS PER SHARE VIEW $-0.12 — THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: